Lucid Genomics provides in-kind access to its genomic analysis platform for laboratories participating in global undiagnosed disease genomics program. By providing our platform in-kind, we hope to help reduce barriers to genomic diagnostics and support Genetic Alliance’s efforts to expand equitable access for patients with rare diseases.” — Uira Souto Melo, Co-Founder and CEO at […]

Beta-site engagement begins as Pictor introduces an integrated 96-well workflow designed for scalable targeted protein analysis in research laboratories. CARLSBAD, Calif. — Pictor Holdings Inc., a global targeted proteomic platform company, today announced the public debut of its next-generation high-resolution platform at ADLM 2026, highlighted by the introduction of the new PictImager®. Designed to support […]

WALTHAM, Mass. — Nova Biomedical today announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Biomedical’s capabilities in cell line development and strengthens its ability to support biopharmaceutical workflows from early development through manufacturing. NanoCellect® WOLF G2® cell sorting platform introduces gentle, microfluidic-based cell selection and isolation, complementing […]

Countable Certified Service Providers are certified by Countable Labs for demonstrated expertise using Countable PCR technology to support studies of all sizes PALO ALTO, Calif. — Countable Labs, the developer of Countable PCR, a breakthrough single-molecule PCR technology redefining how science measures biology, today announced its Countable Certified Service Provider (CSP) program. The Countable CSP […]

Pythia Biosciences and Lexogen recently announced a strategic partnership to empower researchers with deeper biological insights by combining Lexogen’s expertise in RNA sequencing and library preparation with Pythia’s multi-omics data curation and analytics capabilities. Through this collaboration, Pythia will offer Lexogen’s wet-lab capabilities via direct sales and as a core component of its newly launched expanded data ecosystem […]

Supporting ADLM’s focus on collaborative, cross-disciplinary solutions that address laboratory workforce and operational challenges Highlighting innovations in mass spectrometry, next-generation sequencing, digital pathology and AI diagnostics Showcasing Roche’s portfolio across core, molecular and pathology labs and point-of-care settings at booth no. 2901 INDIANAPOLIS — (SIX: RO, ROP; OTCQX: RHHBY) As clinical laboratories face ongoing staffing […]

immunoMUSE® enables flexible, high-sensitivity multiplex immunofluorescence with user-defined antibodies. Schlieren, Switzerland – arcoris bio, a Swiss life science research tools and in vitro diagnostics company, today announced a distribution partnership with Europa Biosite, a leading distributor of life science research products and services. Through this partnership, Europa Biosite will distribute arcoris bio’s newly launched immunoMUSE® kits in […]

Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows ROCKVILLE, Md. — MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership […]

Partnership combines Sirona Dx‘s technology-agnostic spatial biology expertise with Parhelia‘s Spatial Station platform to improve reproducibility, increase throughput, and reduce costs across spatial biology workflows. ASHLAND, Ore. and PORTLAND, Ore. — Parhelia Biosciences and Sirona Dx today announced a strategic partnership aimed at advancing the adoption of spatial biology in translational research, clinical trials, and precision health […]

Highlights combined company’s strong financial position with over $900 million expected at closing, Treeline’s deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expected new program clinical starts Includes headline Phase 1 monotherapy data for TLN-121 in relapsed or refractory lymphomas with overall response rate of 84%, complete response rate of 32% and no […]